Georgia Doctors Urged Kemp to Veto Medical Cannabis Bill SB 220

The Veto Request and Its Core Claims

Georgia physicians sent Governor Kemp a formal letter requesting he veto SB 220 before it became law, arguing the bill would harm public health. Multiple medical professionals signed it. They contended that expanding qualifying conditions and access points would increase youth cannabis use and undermine Georgia's existing prescription drug monitoring framework.

SB 220 passed the Georgia legislature in April 2026 and reached Kemp's desk in early May. The bill adds chronic pain, opioid-use disorder, and intractable pain to the list of qualifying conditions. It also permits nurse practitioners and physician assistants to issue medical cannabis certifications, not just physicians.

The physician coalition's letter cited three peer-reviewed studies as evidence, but none examined Georgia's program. Two studied recreational cannabis markets in Colorado and Washington, while the third analyzed prescription opioid trends in states with any form of medical cannabis law—not program expansions like the one SB 220 represents.

Youth-Use Claims Lack Georgia-Specific Evidence

The letter's central claim rests on studies of recreational markets, not medical programs. One cited study tracked youth use in Colorado after recreational legalization in 2014. Georgia's bill doesn't legalize recreational sales or possession.

Georgia's current medical cannabis program, established in 2015 and expanded in 2019, operates under a closed-loop registry system where patients must register with the Georgia Department of Public Health and dispensaries scan registry cards at point of sale. The system doesn't permit home cultivation or over-the-counter purchases.

The letter didn't cite data from Georgia's existing registry, which has enrolled approximately 28,000 patients since 2019. State data shows no statistically significant change in youth cannabis use rates between 2019 and 2024, according to the Georgia Department of Behavioral Health and Developmental Disabilities' annual youth risk survey.

Opioid-Substitution Evidence Contradicts the Letter's Position

One study the physicians cited actually supports SB 220's opioid-use-disorder provision. It contradicts their argument. The 2022 study published in JAMA Internal Medicine found that states with active medical cannabis programs saw a 6.38 percent reduction in opioid prescriptions for Medicare Part D enrollees compared to states without such programs.

SB 220 explicitly adds opioid-use disorder as a qualifying condition. The bill's sponsor, State Senator Elena Parent, stated in floor remarks that the provision was designed to offer an alternative pathway for patients at risk of opioid dependency. The physician letter didn't address this substitution effect or explain why the cited study's findings shouldn't apply to Georgia.

Georgia's opioid overdose death rate was 18.2 per 100,000 residents in 2024, above the national average of 16.1, according to the Centers for Disease Control and Prevention. The state has no existing statutory alternative for opioid-dependent patients seeking non-narcotic pain management outside of traditional prescription channels.

Prescription Monitoring Argument Misreads the Bill's Text

The letter claimed SB 220 would bypass Georgia's Prescription Drug Monitoring Program, but the bill doesn't alter PDMP reporting requirements. Georgia law requires all Schedule II-IV controlled substance prescriptions to be reported to the PDMP within 24 hours. Medical cannabis isn't a controlled substance under Georgia law. It's a regulated product under the Georgia Access to Medical Cannabis Commission's authority.

The commission, established in 2019, maintains its own patient registry separate from the PDMP. SB 220 doesn't change this structure. The bill requires nurse practitioners and physician assistants to verify patient eligibility through the commission's registry before issuing certifications—the same process physicians currently follow.

The letter's authors didn't respond to a request for comment on whether they believe medical cannabis should be reclassified as a controlled substance to trigger PDMP reporting. Such a reclassification would require separate legislation and would conflict with the commission's statutory mandate to regulate cannabis outside the controlled-substance framework.

What Happens Next

Governor Kemp signed SB 220 into law on May 12, 2026, ten days after receiving the physician coalition's letter. The law takes effect January 1, 2027. The Georgia Access to Medical Cannabis Commission has six months to update its registry system and issue guidance for nurse practitioners and physician assistants seeking certification authority.

Andrew Turnage, the commission's executive director, said in a May 15 statement that the agency expects to begin accepting applications from non-physician providers in November 2026. The commission will require applicants to complete a four-hour continuing education course on Georgia's medical cannabis law and dosing guidelines.

For full background on Georgia's medical cannabis framework and prior legislative expansions, see the CannIntel topic hub on Georgia Medical Cannabis Program. The next regulatory deadline: commission guidance documents due by October 31, 2026.